Cymbalta helps fibromyalgia pain, Lilly says

Eli Lilly and Co.’s depression drug Cymbalta dampened pain in patients with fibromyalgia and has asked the Food and Drug Administration to approve it for secondary use, the Indianapolis pharmaceutical maker said today. Patients experienced less pain beginning a week after taking the treatment, a study showed.

Two percent to 4 percent of Americans, mostly women, suffer from the chronic condition, which causes fatigue as well as pain in muscles, ligaments and tendons.

Cymbalta generated $519.5 million of Lilly’s $4.6 billion in second-quarter sales.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}